Wells Fargo Adjusts Price Target on Amgen to $390 From $375, Maintains Equalweight Rating

robot
Abstract generation in progress

Wells Fargo has increased its price target for Amgen (AMGN) to $390 from $375, while reiterating an Equalweight rating on the stock. This adjustment reflects an updated outlook for the biotechnology giant. Amgen’s stock information, company profile, and other related news are also provided.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments